Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep;36(3):475-489.
doi: 10.1007/s10555-017-9694-9.

Checkpoint immunotherapy in head and neck cancers

Paul Zolkind  1 , Ravindra Uppaluri  2
Affiliations
Review

Checkpoint immunotherapy in head and neck cancers

Paul Zolkind et al. Cancer Metastasis Rev. 2017 Sep.

Abstract

Checkpoint inhibitors have recently gained FDA approval for the treatment of cisplatin-resistant recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) by outperforming standard of care chemotherapy and inducing durable responses in a subset of patients. These monoclonal antibodies unleash the patient's own immune system to target cancer cells. HNSCC is a good target for these agents as there is ample evidence of active immunosurveillance in the head and neck and a number of immune evasion mechanisms by which HNSCCs form progressive disease including via the PD-1/PD-L1 axis. As HNSCCs typically possess a moderately high mutation burden, they should express numerous mutation-derived antigen targets for immune detection. However, with response rates less than 20% in clinical trials, there is a need for biomarkers to screen patients as well as clinical trials evaluating novel combinations to improve outcomes. The aim of this review is to provide historical and mechanistic context for the use of checkpoint inhibitors in head and neck cancer and provide a perspective on the role of novel checkpoints, biomarkers, and combination therapies that are evolving in the near term for patients with HNSCC.

Keywords: Checkpoint blockade; Head and neck squamous cell carcinoma; Immunotherapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
T cell priming and effector function
Fig. 2
Fig. 2
Future directions in personalized immuno-oncology
See this image and copyright information in PMC

References

    1. Warnakulasuriya S (2009). Global epidemiology of oral and oropharyngeal cancer. Oral Oncol, 45(4–5), 309–316, doi:10.1016/j.oraloncology.2008.06.002. - DOI - PubMed
    1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363(8), 711–723, doi:10.1056/NEJMoa1003466. - DOI - PMC - PubMed
    1. Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al. (2016). Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med, 375(19), 1856–1867, doi:10.1056/NEJMoa1602252. - DOI - PMC - PubMed
    1. Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. (2016). Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort. Journal of Clinical Oncology, 34(32), 3838–3845. - PMC - PubMed
    1. Whiteside TL, Letessier E, Hirabayashi H, Vitolo D, Bryant J, Barnes L, et al. (1993). Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer research, 53(23), 5654–5662. - PubMed

MeSH terms

Substances